No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Nonacog Alfa is a type of hematological drug used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. It is a recombinant form of factor VIII, a protein that helps the body form clots. Nonacog Alfa is used to replace the missing factor VIII in patients with hemophilia A, allowing them to form clots and stop bleeding. It is administered intravenously or subcutaneously, depending on the patient's needs.
Nonacog Alfa is a relatively new drug, having been approved by the US Food and Drug Administration in 2014. It is currently marketed by several companies, including Novo Nordisk, Pfizer, and Biogen. Other companies, such as Shire, Bayer, and CSL Behring, also produce similar drugs for the treatment of hemophilia A. Show Less Read more
